Last update 28 Mar 2025

Tuspetinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TUS, C0WUS7XXE9, HM 43239
+ [1]
Action
inhibitors
Mechanism
FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H33ClN6
InChIKeyFZLSDZZNPXXBBB-KDURUIRLSA-N
CAS Registry2294874-49-8

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adult Acute Myeloblastic LeukemiaPhase 2
United States
11 Mar 2019
Adult Acute Myeloblastic LeukemiaPhase 2
Australia
11 Mar 2019
Adult Acute Myeloblastic LeukemiaPhase 2
Germany
11 Mar 2019
Adult Acute Myeloblastic LeukemiaPhase 2
New Zealand
11 Mar 2019
Adult Acute Myeloblastic LeukemiaPhase 2
Spain
11 Mar 2019
Chronic Myelomonocytic LeukemiaPhase 2
United States
11 Mar 2019
Chronic Myelomonocytic LeukemiaPhase 2
Australia
11 Mar 2019
Chronic Myelomonocytic LeukemiaPhase 2
Germany
11 Mar 2019
Chronic Myelomonocytic LeukemiaPhase 2
New Zealand
11 Mar 2019
Chronic Myelomonocytic LeukemiaPhase 2
Spain
11 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Acute Myeloid Leukemia
First line
TP53 Mutation
4
ideliybcjs(fzmtldbsrv) = ehzpadtazl ykleronqgf (yuorabztsv )
Positive
12 Feb 2025
ASH2024
ManualManual
Phase 1
Acute Myeloid Leukemia
RAS Mutation (Activating) | FLT3 Mutation | TP53 Mutation
172
dxflgtoeof(gfjczvognc) = kmwhwgfclb zcatdxugfi (ynaembbuob )
Positive
09 Dec 2024
(VEN-naïve)
dxflgtoeof(gfjczvognc) = nemvovfvut zcatdxugfi (ynaembbuob )
Phase 1
172
(FLT3 mutated)
olfnqnlibv(kddnkglpto) = lgddyynshd wrlidajkid (jyzbvjnqgc )
Positive
09 Dec 2024
(all-comer VEN-naïve)
olfnqnlibv(kddnkglpto) = tvjbibdnrx wrlidajkid (jyzbvjnqgc )
Phase 1/2
170
Tuspetinib (TUS) 20-200mg
tttbjwjczs(gqlydmeuwx) = zrlzmrcqoh jloapihiio (rdwctiudtl )
Positive
14 May 2024
Tuspetinib Venetoclax/Venetoclax (VEN) 400mg
wovshbdjrs(dmxeksdohl) = dqwekrplfh zjewngbryb (gkfiaqzaac )
Phase 1/2
117
jxlxtptvqr(gfulizkgvr) = wvgjzxxiuv frdkkyvtwe (gbgwuqxnfi )
Positive
09 Dec 2023
jxlxtptvqr(gfulizkgvr) = bpmrqtaxlo frdkkyvtwe (gbgwuqxnfi )
Phase 1/2
100
Tuspetinib 20mg to 200mg
(Parts A/B)
gyddcqialm(inakunjytq) = One patient experienced a DLT (Grade 3 muscular weakness) at 200 mg which demonstrated partial improvement at the time of treatment discontinuation (9 days after AE onset). vcnvkccyqk (asrkkgdfeb )
Positive
09 Dec 2023
Tuspetinib 120 mg
(Part C)
Phase 1/2
-
qfslbmyhqf(agkdpufqiw) = hodousyvza xizlytgydp (hlhvgjnxvt )
-
12 May 2022
Phase 1/2
28
bznrlolssc(gedtthrkhk) = diarrhea (14%), nausea (7%), vomiting (7%) and alanine aminotransferase increased (7%), and no drug related > Grade 3 TEAEs were observed to date twsxybscwf (bsveeipiiq )
Positive
05 Nov 2021
(80 mg dose)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free